Valuation: Evolus, Inc.

Market Cap 38Cr 33Cr 31Cr 29Cr 54Cr 3.67TCr 55Cr 366.81Cr 143.96Cr 1.83TCr 144.44Cr 141.26Cr 6.13TCr P/E 2026 *
-11.8x
P/E 2027 * -39.8x
Enterprise Value 51Cr 44Cr 41Cr 38Cr 72Cr 4.88TCr 73Cr 487.93Cr 191.5Cr 2.43TCr 192.13Cr 187.91Cr 8.15TCr EV / Sales 2026 *
1.55x
EV / Sales 2027 * 1.33x
Free-Float
83.36%
Yield 2026 *
-
Yield 2027 * -
1 day-2.83%
1 week-2.34%
1 month-13.35%
3 months+9.57%
6 months+24.52%
Current year-12.18%
1 week 5.72
Extreme 5.7201
6.43
1 month 5.44
Extreme 5.445
7.24
Current year 3.86
Extreme 3.86
7.32
1 year 3.86
Extreme 3.86
9.35
3 years 3.86
Extreme 3.86
17.82
5 years 3.86
Extreme 3.86
17.82
10 years 2.85
Extreme 2.85
39.5
Manager TitleAgeSince
Chief Executive Officer 48 06/05/2018
Director of Finance/CFO 48 08/09/2025
Chief Operating Officer - 01/09/2022
Director TitleAgeSince
Chairman 63 01/01/2018
Director/Board Member 71 12/02/2018
Director/Board Member 48 06/05/2018
Date Insider Type Main position Quantity % Market Cap.
16/03/26 Fiscal year

Chief Executive Officer

2,51,698 0.3891%
17/02/26 Free

Chief Financial Officer

4,20,449 0.6500%
17/02/26 Free

Chief Technology Officer

3,28,475 0.5078%
Change 5-day change 1-year change 3-year change Capi.($)
-2.83%-2.34%-36.17%-42.58% 38Cr
-0.53%-3.95%+50.70%+153.56% 1,02400Cr
+0.21%-2.68%+53.20%+51.79% 62TCr
-2.51%-3.25%+28.54%+68.94% 44TCr
+0.06%-0.42%+37.53%+30.67% 35TCr
-0.69%-0.30%+13.76%+12.83% 26TCr
-7.37%-4.40%-0.74%-44.28% 21TCr
-0.64%+2.43%+29.74%+65.93% 21TCr
-0.82%+0.70%+15.05%+72.05% 16TCr
+0.40%+1.92%+6.47%-29.77% 14TCr
Average -1.47%-1.33%+19.81%+33.91% 34.19TCr
Weighted average by Cap. -1.00%-2.02%+36.13%+71.89%

Financials

2026 *2027 *
Net sales 33Cr 29Cr 27Cr 25Cr 46Cr 3.15TCr 47Cr 315.17Cr 123.69Cr 1.57TCr 124.1Cr 121.38Cr 5.27TCr 39Cr 34Cr 31Cr 29Cr 54Cr 3.7TCr 55Cr 369.74Cr 145.11Cr 1.84TCr 145.59Cr 142.4Cr 6.18TCr
Net income -3.33Cr -2.9Cr -2.69Cr -2.47Cr -4.67Cr -317.95Cr -4.74Cr -32Cr -12Cr -158.29Cr -13Cr -12Cr -530.77Cr -1.06Cr -91.81L -85.46L -78.46L -1.48Cr -100.82Cr -1.5Cr -10Cr -3.95Cr -50Cr -3.97Cr -3.88Cr -168.3Cr
Net Debt 13Cr 11Cr 10Cr 9.43Cr 18Cr 1.21TCr 18Cr 121.13Cr 48Cr 603.56Cr 48Cr 47Cr 2.02TCr 13Cr 11Cr 11Cr 9.81Cr 19Cr 1.26TCr 19Cr 125.9Cr 49Cr 627.32Cr 50Cr 48Cr 2.1TCr
Logo Evolus, Inc.
Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins and injectable hyaluronic acid gels. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and certain European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe.
Employees
350
Date Price Change Volume
31/26/31 $5.840 -2.83% 6,08,876
30/26/30 $6.010 -0.33% 4,24,533
29/26/29 $6.030 -3.05% 8,12,690
28/26/28 $6.220 +0.65% 5,99,640
27/26/27 $6.180 +3.34% 6,50,244
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
5.840USD
Average target price
14.67USD
Spread / Average Target
+151.14%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EOLS Stock